These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15242694)

  • 1. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
    Bozcuk H; Uslu G; Samur M; Yildiz M; Ozben T; Ozdoğan M; Artaç M; Altunbaş H; Akan I; Savaş B
    Cytokine; 2004 Jul 21-Aug 7; 27(2-3):58-65. PubMed ID: 15242694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
    Zhang GJ; Adachi I
    Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
    Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
    Rich T; Innominato PF; Boerner J; Mormont MC; Iacobelli S; Baron B; Jasmin C; Lévi F
    Clin Cancer Res; 2005 Mar; 11(5):1757-64. PubMed ID: 15755997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
    Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
    Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
    Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
    Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between insulin resistance and serum concentrations of IL-6 and TNF-alpha in overweight or obese women with early stage breast cancer.
    Gonullu G; Ersoy C; Ersoy A; Evrensel T; Basturk B; Kurt E; Oral B; Gokgoz S; Manavoglu O
    Cytokine; 2005 Aug; 31(4):264-9. PubMed ID: 15955709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
    Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
    Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
    Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
    Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate--preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy.
    Grim-Stieger M; Keilani M; Mader RM; Marosi C; Schmidinger M; Zielinski CC; Fialka-Moser V; Crevenna R
    Eur J Cancer Care (Engl); 2008 Sep; 17(5):454-62. PubMed ID: 18637115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer.
    Makino T; Noguchi Y; Yoshikawa T; Doi C; Nomura K
    Br J Surg; 1998 Dec; 85(12):1658-62. PubMed ID: 9876070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.